Literature DB >> 26378131

Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users.

Dayong Lee1, Mateus M Bergamaschi2, Garry Milman1, Allan J Barnes1, Regina H C Queiroz3, Ryan Vandrey4, Marilyn A Huestis5.   

Abstract

More Americans are dependent on cannabis than any other illicit drug. The main analytes for cannabis testing include the primary psychoactive constituent, Δ(9)-tetrahydrocannabinol (THC), equipotent 11-hydroxy-THC (11-OH-THC) and inactive 11-nor-9-carboxy-THC (THCCOOH). Eleven adult chronic frequent cannabis smokers resided on a closed research unit with unlimited access to 5.9% THC cannabis cigarettes from 12:00 to 23:00 during two ad libitum smoking phases, followed by a 5-day abstinence period in seven participants. A single cigarette was smoked under controlled topography on the last day of the smoking and abstinence phases. Plasma cannabinoids were quantified by two-dimensional gas chromatography-mass spectrometry. Median plasma maximum concentrations (Cmax) were 28.3 (THC), 3.9 (11-OH-THC) and 47.0 μg/L (THCCOOH) 0.5 h after controlled single cannabis smoking. Median Cmax 0.2-0.5 h after ad libitum smoking was higher for all analytes: 83.5 (THC), 14.2 (11-OH-THC) and 155 μg/L (THCCOOH). All 11 participants' plasma samples were THC and THCCOOH-positive, 58.3% had THC ≥5 μg/L and 79.2% were 11-OH-THC-positive 8.1-14 h after last cannabis smoking. Cannabinoid detection rates in seven participants 106-112 h (4-5 days) after last smoking were 92.9 (THC), 35.7 (11-OH-THC) and 100% (THCCOOH), with limits of quantification of 0.5 μg/L for THC and THCCOOH, and 1.0 μg/L for 11-OH-THC. These data greatly expand prior research findings on cannabinoid excretion profiles in chronic frequent cannabis smokers during ad libitum smoking. Smoking multiple cannabis cigarettes led to higher Cmax and AUC compared with smoking a single cigarette. The chronic frequent cannabis smokers exhibited extended detection windows for plasma cannabinoids, reflecting a large cannabinoid body burden. Published by Oxford University Press 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26378131      PMCID: PMC4570940          DOI: 10.1093/jat/bkv082

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  40 in total

1.  Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.

Authors:  David M Schwope; Erin L Karschner; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2011-08-11       Impact factor: 8.327

2.  Antagonist-elicited cannabis withdrawal in humans.

Authors:  David A Gorelick; Robert S Goodwin; Eugene Schwilke; David M Schwope; William D Darwin; Deanna L Kelly; Robert P McMahon; Fang Liu; Catherine Ortemann-Renon; Denis Bonnet; Marilyn A Huestis
Journal:  J Clin Psychopharmacol       Date:  2011-10       Impact factor: 3.153

3.  Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers.

Authors:  J Hirvonen; R S Goodwin; C-T Li; G E Terry; S S Zoghbi; C Morse; V W Pike; N D Volkow; M A Huestis; R B Innis
Journal:  Mol Psychiatry       Date:  2011-07-12       Impact factor: 15.992

4.  Cannabis findings in drivers suspected of driving under the influence of drugs in Finland from 2006 to 2008.

Authors:  Tom Blencowe; Anna Pehrsson; Sirpa Mykkänen; Teemu Gunnar; Pirjo Lillsunde
Journal:  Forensic Sci Int       Date:  2011-10-22       Impact factor: 2.395

5.  Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Ronald I Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

6.  Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing.

Authors:  Eugene W Schwilke; Erin L Karschner; Ross H Lowe; Ann M Gordon; Jean Lud Cadet; Ronald I Herning; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-03-05       Impact factor: 8.327

7.  Driving under the influence of cannabis: a 10-year study of age and gender differences in the concentrations of tetrahydrocannabinol in blood.

Authors:  Alan W Jones; Anita Holmgren; Fredrik C Kugelberg
Journal:  Addiction       Date:  2008-01-08       Impact factor: 6.526

8.  Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users.

Authors:  J G Ramaekers; G Kauert; E L Theunissen; S W Toennes; M R Moeller
Journal:  J Psychopharmacol       Date:  2008-08-21       Impact factor: 4.153

9.  Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Harrison G Pope; Ronald Herning; Jean L Cadet; Marilyn A Huestis
Journal:  Addiction       Date:  2009-10-05       Impact factor: 6.526

10.  Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users.

Authors:  Johannes G Ramaekers; Eef L Theunissen; Marjolein de Brouwer; Stefan W Toennes; Manfred R Moeller; Gerhold Kauert
Journal:  Psychopharmacology (Berl)       Date:  2010-10-30       Impact factor: 4.530

View more
  10 in total

1.  Ultra-high performance liquid chromatography tandem mass-spectrometry for simple and simultaneous quantification of cannabinoids.

Authors:  Rohitash Jamwal; Ariel R Topletz; Bharat Ramratnam; Fatemeh Akhlaghi
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-02-06       Impact factor: 3.205

Review 2.  Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.

Authors:  Benedikt Fischer; Cayley Russell; Pamela Sabioni; Wim van den Brink; Bernard Le Foll; Wayne Hall; Jürgen Rehm; Robin Room
Journal:  Am J Public Health       Date:  2017-06-23       Impact factor: 9.308

3.  Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas Chromatography-Tandem Mass Spectrometry.

Authors:  David M Andrenyak; David E Moody; Matthew H Slawson; Daniel S O'Leary; Margaret Haney
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

4.  Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.

Authors:  Suhas Ganesh; Jose Cortes-Briones; Mohini Ranganathan; Rajiv Radhakrishnan; Patrick D Skosnik; Deepak Cyril D'Souza
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

5.  Determination of Cannabinoid Vapor Pressures to Aid in Vapor Phase Detection of Intoxication.

Authors:  Tara M Lovestead; Thomas J Bruno
Journal:  Forensic Chem       Date:  2017-06-27

6.  Assessment of transient dopamine responses to smoked cannabis.

Authors:  Katina C Calakos; Heather Liu; Yihuan Lu; Jon Mikael Anderson; David Matuskey; Nabeel Nabulsi; Yunpeng Ye; Patrick D Skosnik; Deepak Cyril D'Souza; Evan D Morris; Kelly P Cosgrove; Ansel T Hillmer
Journal:  Drug Alcohol Depend       Date:  2021-07-29       Impact factor: 4.852

7.  Reelin deficiency contributes to long-term behavioral abnormalities induced by chronic adolescent exposure to Δ9-tetrahydrocannabinol in mice.

Authors:  Attilio Iemolo; Patricia Montilla-Perez; Jacques Nguyen; Victoria B Risbrough; Michael A Taffe; Francesca Telese
Journal:  Neuropharmacology       Date:  2021-02-11       Impact factor: 5.250

8.  Effects of repeated adolescent exposure to cannabis smoke on cognitive outcomes in adulthood.

Authors:  Caesar M Hernandez; Caitlin A Orsini; Shelby L Blaes; Jennifer L Bizon; Marcelo Febo; Adriaan W Bruijnzeel; Barry Setlow
Journal:  J Psychopharmacol       Date:  2020-12-09       Impact factor: 4.562

Review 9.  Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding.

Authors:  Anaëlle Monfort; Ema Ferreira; Grégoire Leclair; Gregory Anton Lodygensky
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

10.  Species-specific susceptibility to cannabis-induced convulsions.

Authors:  Benjamin J Whalley; Hong Lin; Lynne Bell; Thomas Hill; Amesha Patel; Roy A Gray; C Elizabeth Roberts; Orrin Devinsky; Michael Bazelot; Claire M Williams; Gary J Stephens
Journal:  Br J Pharmacol       Date:  2018-03-25       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.